MMV’s Global Safety Board (GSB) was instituted in 2009 and is mandated to conduct a review on projects that are progressing to testing for the first time in humans. The board continues to conduct a thorough scientific and ethical review at each major project milestone beyond the clinical phase 1 of the R&D process, through to registration and distribution.
Global Safety Board Members
Dr Trevor Gibbs Independent Consultant, Former Senior Vice President, Pharmacovigilance & Medical Governance, GlaxoSmithKline, UK; and Co-Chairman of MMV Global Safety Board, UK
Dr Stephan Duparc Chief Medical Officer, MMV, Switzerland; and Co-Chairman of MMV Global Safety Board
Sir Colin Dollery Former Senior Consultant, Glaxo-SmithKline Research and Development, UK
Prof. Tim Hammond Pharmaceutical Preclinical Safety Consultant, UK
Prof Pieter Joubert Clinical Pharmacology Consultant, UK
Dr John Pears Director, Woodhouse Green, UK